Najat Khan's Insider Trades & SAST Disclosures

Najat Khan's most recent trade in Recursion Pharmaceuticals Inc - Ordinary Shares - Class A was a trade of 3,796 Class A Common Stock done at an average price of $4.3 . Disclosure was reported to the exchange on May 15, 2025.

Share

Note

This is a custom search result for pattern Najat Khan.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.

All Superstars

"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches "Balanced Fund" but not "Balanced Growth Fund" Balanced Fund: Use this format without quotation marks to search for all funds related to the term "Balanced Fund" The results may include "Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".

Stock	Client Name	Client Category	Action	Reported to Exchange	Quantity	Post Transaction Holding	Traded %	Avg. Price	Value	Security Type
Recursion Pharmaceuticals ...	Najat Khan	Director, Chief R&D Commercial Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.25 per share.	15 May 2025	3,796	708,585	-	4.3	16,133	Class A Common Stock
Recursion Pharmaceuticals ...	Najat Khan	Director, Chief R&D Commercial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Feb 2025	420,226	420,226	-		-	Stock Option (Right to Buy)
Recursion Pharmaceuticals ...	Najat Khan	Director, Chief R&D Commercial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Feb 2025	210,113	707,085	-		0	Class A Common Stock
Recursion Pharmaceuticals ...	Najat Khan	Director, Chief R&D Commercial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	03 Feb 2025	8,049	715,134	-		0	Class A Common Stock
Recursion Pharmaceuticals ...	Najat Khan	Director, Chief R&D Commercial Officer	Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.25 per share.	03 Feb 2025	2,753	712,381	-	7.2	19,959	Class A Common Stock
Recursion Pharmaceuticals ...	Najat Khan	Director, Chief R&D Commercial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Aug 2024	993,944	993,944	-		-	Stock Option (Right to Buy)
Recursion Pharmaceuticals ...	Najat Khan	Director, Chief R&D Commercial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Aug 2024	496,972	496,972	-		0	Class A Common Stock

*All Values are in $ Million

Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures

Data as reported to USA Exchanges

View All The Insider Trades